Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease.

Markku S. Nieminen(Cornell University), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), Kimmo Kontula, Kari Mattila(University of Helsinki), M. Valle(University of Helsinki), Christian Ehnholm(University of Helsinki), Matti Jauhiainen(Finnish Institute for Health and Welfare), T Kuusi(University of Helsinki), Katriina Aalto‐Setälä(Tampere University)

Arteriosclerosis and Thrombosis A Journal of Vascular Biology

January 1, 1992

10.1161/01.atv.12.1.58

Cited by 99

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

FinnGen provides genetic insights from a well-phenotyped isolated population

|Nature|2023|4.2k

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

|European Heart Journal|2017|3.8k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

|European Heart Journal|2011|3.5k